MAPT and Schnyder corneal dystrophy: Previous studies have suggested that cerebrospinal fluid biomarkers, including low amyloidβ-42 (Aβ-42) and high tau levels, are more common in SCD patients compared with normal controls (NC), and that low Aβ-42 may be a good predictor of clinical progression in SCD [9, 10].